Empowering Leadership, Driving Innovation

Management Board

Get to know our leadership team driving our pioneering initiatives driving force behind Evotec's scientific excellence and strategic growth.

Headshot of Christian Wojczewsk
Evotec logo big

Dr Christian Wojczewski

Chief Executive Officer

Evotec logo big

Latest update: July 2024

Biography


Dr Christian Wojczewski (born in 1971, German citizen) joined Evotec as Chief Executive Officer and Chairman of the Management Board on 01 July 2024. Dr Wojczewski has over 20 years of experience in various top management positions, most recently at Mediq and Linde Healthcare. He is an experienced CEO with a proven track record in building and leading large, high-performing life science organisations, and with deep strategic, operational and transformational expertise. Dr Wojczewski holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe-University in Frankfurt am Main. He worked as a manager at McKinsey for companies in the life science and chemical industries in Europe and the USA. In 2005, he joined Linde, the global market leader for medical and industrial gases. After various roles within the company, Dr Wojczewski took over as Head of Group Strategy and later additionally assumed leadership of Linde Healthcare, one of the Group’s key growth businesses. During his tenure, Linde Healthcare developed into the global market leader for medical gases and services for patients with chronic respiratory diseases operating in more than 60 countries. In 2017, Dr Wojczewski joined Mediq in the Netherlands, a European leader in medical devices and related services, as group CEO. Under Dr Wojczewski’s leadership, Mediq achieved an impressive turnaround with strong EBITDA recovery and towards profitable growth

Evotec logo big
Headshot of Laetitia Rouxel
Evotec logo big

Laetitia Rouxel

Chief Financial Officer

Evotec logo big

Latest update: April 2024

Biography

Laetitia Rouxel (born in 1973, French citizen) joined Evotec as Chief Financial Officer and Member of the Management Board on 01 April 2023. Rouxel has more than 25 years of finance experience in various sectors such as Life Sciences, Food, Cosmetics and Building industry. A graduate of the French Business school ISG, she started her career with finance and commercial roles in the Pharma industry at Pfizer and J&J. She went on to work for the French multinational food-products corporation Danone, where she covered various leading Finance positions in multiple regions for R&D, Medical and Baby Nutrition based in France and in the Netherlands. She then joined the beauty company Coty in Switzerland, where she became divisional CFO. Before joining Evotec, she was Global CFO of Wavin, a solutions leader for the building and infrastructure industry.

Evotec logo big
Headshot of Cord Dohrmann
Evotec logo big

Dr Cord Dohrmann

Chief Scientific Officer

Evotec logo big

Latest update: April 2024

Biography 

Dr Cord Dohrmann (born in 1964, German citizen) joined Evotec as Chief Scientific Officer and Member of the Management Board in 2010. Dr Dohrmann has spent over 25 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr Dohrmann completed his MA thesis at the Max Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining a Max Planck Institute spin-off company, DeveloGen, in 1999. During his ten-year tenure, he served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr Cord Dohrmann is a member of the Supervisory Boards of Eternygen and Breakpoint Therapeutics, a Non-Executive Member of the Board of Directors of Facio Therapies and a Board Observer of Immunitas Inc. He has been advising the European Commission, the Max Planck Institute as well as various venture capital firms. In February 2021, Dr Dohrmann was appointed to the German Council of Science and Humanities.

Evotec logo big
Headshot of Matthias Evers
Evotec logo big

Dr Matthias Evers

Chief Business Officer

Evotec logo big

Latest update: May 2024

Biography 


Matthias (born in 1973, German citizen) was appointed as Chief Business Officer of Evotec on 01 May 2022. Matthias is responsible for business development, digital technology, and strategy across the entire company. Prior to joining Evotec, Matthias accumulated 20 years of experience as Senior Partner with the consulting firm McKinsey & Company where he co-led R&D in Life Sciences globally and served on the Firm’s most senior Knowledge and People Committees, respectively. He also spearheaded venture-type, company building efforts for biotech and health tech companies in Europe. Matthias gained significant exposure to the U.S., China, India, and Europe, where he helped R&D organisations to excel at innovation through large-scale performance transformations, innovation programmes, and novel approaches for maximising value from new assets, capabilities, and technologies. His areas of expertise include convergence of biology and technology, which he published widely around “The Bio Revolution”, as well as creating patient benefits from ecosystem-wide, cross-industry collaboration (e.g., in the context of public-private partnerships or industry fora he helped create like in Medical Affairs or Regulatory Affairs). Further, Matthias has served as advisor and speaker at high-profile science events, including the Lindau Nobel Laureate Meetings and Global Biotech Revolution’s GapSummit for young researchers.


Matthias was a Postdoctoral Fellow at the Center for Molecular Neurobiology Hamburg (ZMNH) and holds a Ph.D. based on his work in molecular biology and bioinformatics from the University of Bochum (Germany) where he also earned his MSc in Biochemistry. He is founding member of the Competence Center Biointelligence e.V. and has led the jury of the Science4Life e.V. startup competition for many years. Since 2024 he is a member of the Advisory/Supervisory Board of Angelini Ventures.

Evotec logo big
Headshot of Craig Johnstone
Evotec logo big

Dr Craig Johnstone

Chief Operating Officer & Site Head Toulouse

Evotec logo big

Latest update: April 2024

Biography

Dr Craig Johnstone (born in 1970, British citizen) was appointed Chief Operating Officer and Member of the Management Board of Evotec on 01 January 2019. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency. From April 2015, Dr Johnstone was Directeur General and Site Head, Evotec (France) SAS, and from January 2017, he was appointed Global Head, Integrated Drug Discovery. Dr Johnstone is a successful drug discovery leader with over 20 years’ experience particularly in the areas of diabetes, inflammation and oncology. Between 1994 and 2012, Dr Johnstone served in a number of project, function, matrix and leadership roles at AstraZeneca, Prosidion and Rapier Research where he led teams and groups, which discovered numerous candidate drugs for clinical development including AZD1656, which reached PhIIb for Type II Diabetes. During this time, Dr Johnstone also developed expertise in LEAN-inspired process excellence in drug discovery and developed a keen interest in the interface between creativity, innovation and process improvement to deliver the highest performance drug discovery, advising teams and implementing multi-site, international change initiatives to drive performance. Dr Johnstone is a Fellow of the Royal Society of Chemistry and Chartered Chemist (FRSC CChem) and holds BSc in Chemistry and a PhD in organic and organometallic synthesis and is an accredited LEAN Sigma Black Belt. He has published more than 70 patents and papers in drug discovery, medicinal and synthetic chemistry, innovation and LEAN methods applied to the inventive processes of drug discovery. Dr Johnstone does not hold any memberships in supervisory bodies.

Evotec logo big
Headshot of Aurelie Dalbiez
Evotec logo big

Aurélie Dalbiez

Chief People Officer

Evotec logo big

Latest update: July 2024

Biography 


Aurélie Dalbiez (born in 1977, French citizen) joined Evotec as Chief People Officer and Member of the Management Board on 15 June 2024. In her role as CPO, Aurélie oversees the development and implementation of Evotec’s people strategy, focusing on fostering a culture of innovation, collaboration, and belonging. With over 25 years of international people leadership experience, Aurélie has a wealth of experience and expertise in Human Resources and a proven track record of driving organizational transformation and fostering employee engagement.


Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer (“CHRO”) at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands. Previously, she was Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career in the banking industry, first at Deutsche Bank and later at Capital Group.


Aurélie brings a multi-cultural background and perspective. She lived in the United States, earned her university degree in International Business in Lyon, France and worked internationally throughout her career, mainly in Switzerland and The Netherlands with assignments in Spain, Germany, and France. She is fluent in French and English and also speaks German and Spanish.

Evotec logo big